Radiologic types of Mycobacterium xenopi pulmonary disease: different patients with similar short-term outcomes Original Article First Online: 14 December 2018 Abstract Mycobacterium xenopi pulmonary disease (Mxe-PD) is common among nontuberculous mycobacterial infections in Europe and Canada. Associations between radiological pattern and clinical features and outcomes are inadequately studied in Mxe-PD. We sought to investigate clinical characteristics and outcomes according to the dominant radiological pattern among patients with Mxe-PD. We retrospectively studied patients with Mxe-PD seen in our clinic, categorizing their predominant CT pattern as nodular bronchiectasis, fibrocavitary, or unclassifiable, and compared clinical characteristics, treatment, and outcomes between radiologic groups. Of 94 patients with Mxe-PD, CT patterns comprised nodular bronchiectasis (40/94, 42.6%), fibrocavitary (37/94, 39.4%), and unclassifiable (17/94, 18.1%). Compared with fibrocavitation, patients with nodular bronchiectasis were female dominant, less often had COPD, less often had AFB smear-positive sputum, and more frequently had co-isolation of Pseudomonas. Patients with nodular bronchiectasis were less often treated (65% versus 91.9%) and when treated, they received fewer anti-mycobacterial drugs (on average 3 versus 4). Outcomes did not differ significantly by radiological pattern. Nodular bronchiectasis was common among Mxe-PD patients in our clinic. Compared with fibrocavitary disease, patients with nodular bronchiectasis had features suggestive of milder disease and were less often treated. Among treated patients, outcomes did not differ by radiologic pattern. Keywords Mycobacterium xenopi Nontuberculous mycobacteria Chest CT Nodular bronchiectasis Electronic supplementary material
The online version of this article (
) contains supplementary material, which is available to authorized users. https://doi.org/10.1007/s10096-018-3437-x Notes Acknowledgement
This work is supported in part by Kurozumi Medical Foundation and Tokyo-Hokenkai Byotai-Seiri Laboratory.
Compliance with ethical standards Conflict of interest
The authors declare that they have no conflict of interest.
The study protocol was reviewed by the University Health Network-Research Ethics Board (Research Ethics Board number 18-5104).
In light of the retrospective design, the requirement of informed consent was waived.
Springer Nature remains neutral with regard to jurisdictionalclaims in published maps and institutional affiliations.
Prevots DR, Marras TK (2015) Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 36:13–34.
https://doi.org/10.1016/j.ccm.2014.10.002 CrossRef PubMed Google Scholar
Marras TK, Mendelson D, Marchand-Austin A et al (2013) Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis 19:1889–1891.
https://doi.org/10.3201/eid1911.130737 CrossRef PubMed PubMedCentral Google Scholar
Hoefsloot W, Van Ingen J, Andrejak C et al (2013) The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 42:1604–1613.
https://doi.org/10.1183/09031936.00149212 CrossRef PubMed Google Scholar
van Ingen J, Boeree MJ, de Lange WCM et al (2008)
clinical relevance and determinants, the Netherlands. Emerg Infect Dis 14:385–389.
https://doi.org/10.3201/eid1403.061393 CrossRef PubMed PubMedCentral Google Scholar
Andrejak C, Lescure F-X, Pukenyte E et al (2009)
pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 64:291–296.
https://doi.org/10.1136/thx.2008.096842 CrossRef PubMed Google Scholar
Griffith DE, Aksamit T, Brown-Elliott BA et al (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367–416.
https://doi.org/10.1164/rccm.200604-571ST CrossRef Google Scholar
Hayashi M, Takayanagi N, Kanauchi T et al (2012) Prognostic factors of 634 HIV-negative patients with
complex lung disease. Am J Respir Crit Care Med 185:575–583.
https://doi.org/10.1164/rccm.201107-1203OC CrossRef PubMed Google Scholar
Ito Y, Hirai T, Maekawa K et al (2012) Predictors of 5-year mortality in pulmonary
complex disease. Int J Tuberc Lung Dis 16:408–414.
https://doi.org/10.5588/ijtld.11.0148 CrossRef PubMed Google Scholar
Hirama T, Marchand-Austin A, Ma J et al (2018)
genotype associated with clinical phenotype in lung disease. Lung 196:213–217.
https://doi.org/10.1007/s00408-018-0087-9 CrossRef PubMed Google Scholar
Hirama T, Brode SK, Beswick J et al (2018) Characteristics, treatment and outcomes of nontuberculous mycobacterial pulmonary disease after allogeneic hematopoietic stem cell transplant. Eur Respir J 51:1702330.
https://doi.org/10.1183/13993003.02330-2017 CrossRef PubMed Google Scholar
Lam PK, Griffith DE, Aksamit TR et al (2006) Factors related to response to intermittent treatment of
complex lung disease. Am J Respir Crit Care Med 173:1283–1289.
https://doi.org/10.1164/rccm.200509-1531OC CrossRef PubMed Google Scholar
van Ingen J, Aksamit T, Andrejak C et al (2018) Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J 51:1800170.
https://doi.org/10.1183/13993003.00170-2018 CrossRef Google Scholar
Marras TK, Wagnetz U, Jamieson FB, Patsios DA (2013) Chest computed tomography predicts microbiological burden and symptoms in pulmonary
. Respirology 18:92–101.
https://doi.org/10.1111/j.1440-1843.2012.02277.x CrossRef PubMed Google Scholar
Carrillo MC, Patsios D, Wagnetz U et al (2014) Comparison of the spectrum of radiologic and clinical manifestations of pulmonary disease caused by
. Can Assoc Radiol J 65:207–213.
https://doi.org/10.1016/j.carj.2013.05.006 CrossRef PubMed Google Scholar
Park SW, Song JW, Shim TS et al (2012) Mycobacterial pulmonary infections in patients with idiopathic pulmonary fibrosis. J Korean Med Sci 27:896–900.
https://doi.org/10.3346/jkms.2012.27.8.896 CrossRef PubMed PubMedCentral Google Scholar
Jo K-W, Kim S, Lee JY et al (2014) Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy. J Infect Chemother 20:602–606.
https://doi.org/10.1016/j.jiac.2014.05.010 CrossRef PubMed Google Scholar
Varadi RG, Marras TK (2009) Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review. Int J Tuberc Lung Dis 13:1210–1218
PubMed Google Scholar
Wallace RJ, Brown-Elliott BA, McNulty S et al (2014) Macrolide/azalide therapy for nodular/bronchiectatic
complex lung disease. Chest 146:276–282.
https://doi.org/10.1378/chest.13-2538 CrossRef PubMed PubMedCentral Google Scholar
Koh W-J, Moon SM, Kim S-Y et al (2017) Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J 50:1602503.
https://doi.org/10.1183/13993003.02503-2016 CrossRef PubMed Google Scholar
Haworth CS, Banks J, Capstick T et al (2017) British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 72:ii1–ii64.
https://doi.org/10.1136/thoraxjnl-2017-210927 CrossRef Google Scholar
Research Committee of the British Thoracic Society (2001) First randomised trial of treatments for pulmonary disease caused by
M avium intracellulare
in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 56:167–172
CrossRef Google Scholar
Diel R, Ringshausen F, Richter E et al (2017) Microbiological and clinical outcomes of treating non-
complex nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis. Chest 152:120–142.
https://doi.org/10.1016/j.chest.2017.04.166 CrossRef PubMed Google Scholar Copyright information
© Springer-Verlag GmbH Germany, part of Springer Nature 2018